RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Australia)

Structure/Sequence

Molecular FormulaC29H36N6O6

InChIKeyPLILLUUXAVKBPY-SBIAVEDLSA-N

CAS Registry496775-62-3

262

Clinical Trials associated with Eltrombopag Diolamine

NCT07660172

/ Not yet recruitingPhase 2

A Phase 2, Open-label, Single-arm Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary Immune Thrombocytopenia Who Had an Insufficient Response to or Relapsed After First-line Corticosteroid Treatment (VAYHIT-P).

The purpose of this study is to assess the efficacy, safety and pharmacokinetics (PK) of ianalumab (VAY736) in addition to eltrombopag treatment; and to inform the dose of ianalumab in pediatric patients (5 to <18 years of age) with primary ITP who have had an insufficient response to or relapsed after first-line treatment with corticosteroids.

Start Date08 Feb 2027

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

NCT07687134

/ Not yet recruitingPhase 2IIT

Eltrombopag Combined With Telitacicept Versus Eltrombopag Monotherapy for the Treatment of Immune Thrombocytopenia Refractory or Relapsed to Corticosteroid Therapy: A Randomized Exploratory, Controlled, Open-label, Phase II Clinical Study

Background: Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder. Corticosteroids are first-line therapy, but about one-third of patients relapse or are refractory. Eltrombopag (a TPO-RA) promotes platelet production, yet some patients show no response or relapse upon discontinuation. Telitacicept, a TACI-Fc fusion protein, dual-targets BAFF and APRIL, inhibiting B cell and plasma cell function and reducing autoantibody production, potentially providing synergistic immunomodulatory benefit.
Objective: To evaluate the sustained response rate of eltrombopag plus telitacicept vs. eltrombopag alone in patients with steroid-refractory/relapsed ITP.
Design: Randomized, open-label, controlled, exploratory Phase II study. 40 patients planned (20 combination, 20 monotherapy). Combination group: eltrombopag + telitacicept . Monotherapy group: eltrombopag alone for 12 weeks. Monotherapy patients with no response after 4 weeks may cross over to the combination group. After 12 weeks, treatment is stopped and patients are followed until Week 24.
Primary endpoint: Proportion of patients maintaining platelet count ≥30×10⁹/L with no bleeding at 24 weeks post-treatment. Secondary endpoints include platelet response rates during 12 weeks, safety, bleeding events, etc.
Expected results: The combination group is expected to have a significantly higher proportion of patients achieving the primary endpoint without increased adverse events.
Population: Age ≥18, diagnosed ITP ≥3 months, baseline platelets <30×10⁹/L, prior corticosteroid failure.
Safety: Monitoring for bleeding, infection, thrombosis, cytopenia, etc., with dose adjustment/cessation as per protocol.
Conclusion: This study explores whether dual-targeting (platelet production + autoimmune suppression) with eltrombopag and telitacicept can provide more durable remission for steroid-refractory/relapsed ITP patients.

Start Date10 Jul 2026

Sponsor / Collaborator-

ChiCTR2600126202

/ Not yet recruitingPhase 3IIT

Efficacy and Safety of Eltrombopag for the Prevention of Thrombocytopenia Following the First Consolidation Chemotherapy in Patients with Acute Myeloid Leukemia: A Multicenter, Randomized, Placebo-Controlled Clinical Trial

Start Date15 Jun 2026

Sponsor / Collaborator

Peking University Shenzhen Hospital

100 Clinical Results associated with Eltrombopag Diolamine

100 Translational Medicine associated with Eltrombopag Diolamine

100 Patents (Medical) associated with Eltrombopag Diolamine

1,469

Literatures (Medical) associated with Eltrombopag Diolamine

31 Dec 2026·Hematology

Efficacy and safety of TPO-RA combined with sirolimus in the treatment of relapsed immune thrombocytopenia

Article

Author: Chen, Xiaoli ; Wang, Dan ; Feng, Yimei ; Zhang, Xi ; Liu, Jia ; Li, Jinqiong ; Tan, Aoxue

BACKGROUND:

Relapsed immune thrombocytopenia (ITP) poses challenges in treatment. Thrombopoietin receptor agonists (TPO-RAs) are recommended as second-line therapy, but the efficacy of monotherapy is limited to about 60%. Our preliminary studies suggest sirolimus is effective for relapsed ITP. This study aimed to evaluate the efficacy and safety of TPO-RA combined with sirolimus in treating relapsed ITP.

METHODS:

A retrospective analysis was conducted on 50 patients with relapsed ITP, all of whom received TPO-RAs (hetrombopag and eltrombopag) combined with sirolimus therapy. The primary endpoints were the overall response rate (ORR) at 4, 8, and 12 weeks of treatment. Secondary endpoints included safety of this regimen and subgroup analysis.

RESULTS:

ORR at 4, 8, and 12 weeks was 61%, 76%, and 82%, respectively, with a median time to response of 7 days. Mean platelet counts at 2-, 4-, 8-, and 12-weeks post-treatment were 71 ± 12.7 × 10⁹/L, 86 ± 10.9 × 10⁹/L, 128 ± 19.7 × 10⁹/L and 131 ± 17.2 × 10⁹/L, respectively. Whether it is hetrombopag or eltrombopag, when combined with sirolimus, there is no statistically significant difference in efficacy between the two subgroups. TPORAs combined with sirolimus as second-line treatment and as third-line or beyond treatment showed no difference in efficacy. Among ANA-positive patients, the ORR shows no significant difference compared to the ANA-negative group (p > 0.05). Patients with ITP for less than one year are more likely to benefit from this treatment regimen (p = 0.003).

CONCLUSIONS:

The combination of TPO-RAs and sirolimus significantly improved platelet counts and sustained response rates. The regimen demonstrated a manageable safety profile, offering a novel therapeutic option for relapsed ITP.

31 Dec 2026·PLATELETS

Single-cell transcriptome deciphers key targets of thrombopoietin receptor agonists and immune microenvironment characteristics of immune thrombocytopenia

Article

Author: Wan, Xiaohan ; Hou, Ming ; Wang, Haoxu ; Wang, Wanru ; Wang, Ruixue ; Cao, Junying

Thrombopoietin receptor agonists (TPO-RAs) represent a cornerstone in immune thrombocytopenia (ITP) management, yet their molecular mechanisms remain incompletely elucidated. This study systematically deciphered the key targets and signaling networks of four TPO-RAs (romiplostim, eltrombopag, avatrombopag, hetrombopag) in ITP pathogenesis. Network pharmacology was integrated with single-cell high-dimensional weighted gene co-expression network analysis (hdWGCNA) using bone marrow scRNA-seq data from ITP patients and healthy controls. Metacell-based co-expression modules to hematopoietic bone marrow cells were identified. Drug targets were curated from multiple databases, and candidate genes were screened by intersecting differentially expressed genes (DEGs), cell specific modules, and TPO-RA targets. Molecular docking, pseudotime trajectory analysis, and in silico gene knockdown were employed for functional validation. Intersection analysis revealed five key genes (CACNA1A, CSF1R, PKN1, CD9, DSTYK). Molecular docking demonstrated strong binding affinities between TPO-RAs and key targets. The ITP bone marrow niche exhibited rewired cell-cell communication, with enhanced T cell-initiated signaling and aberrant megakaryocyte-T cell interactions. Pseudotime analysis uncovered disrupted megakaryocyte maturation dynamics. In silico knockdown revealed CACNA1A, CSF1R, and PKN1 dysregulation exacerbated neutrophil hyperactivity, while CD9 and DSTYK knockdown impaired mitotic regulation. This study delineated mechanisms of TPO-RAs, highlighting five key genes that orchestrate dysregulated thrombopoiesis and immune dysfunction in ITP. The integration of in silico strategies identified novel targets for optimizing ITP therapy.

01 Jul 2026·PEDIATRIC BLOOD & CANCER

Isolated Dermal Arteriolar Thrombosis in a Pediatric Patient: A Rare Complication During Eltrombopag Therapy for Chronic Immune Thrombocytopenia

Letter

Author: Takada, Hidetoshi ; Takemura, Noriko ; Saito, Koyumi ; Fukushima, Hiroko ; Nishigami, Naoko ; Fujita, Takashi ; Hosaka, Sho ; Yamaki, Yuni

News (Medical) associated with Eltrombopag Diolamine

07 Jul 2026

·www.fiercepharma.com

Novartis dismisses 322 more staffers based out of US headquarters

Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees pink slips. The cuts will go into effect by Oct. 2, according to a Worker Adjustment and Retraining Notification (WARN) Act filing with the Garden State. Novartis is making changes to its field sales, patient support and marketing organizations to “enhance operational efficiency and ensure we are investing resources where they can have the greatest impact," a company spokesperson wrote in an emailed statement. "As a result, some roles are impacted." “Novartis continually evaluates opportunities to align our organization with evolving patient, customer and business needs,” the spokesperson added. It is the fourth round of dismissals over the last five months at the East Hanover site. The other three rounds of cuts, which also were listed in WARN reports, will cost a total of 250 employees their jobs. In March, Novartis moved to eliminate 114 roles at its U.S. home base and explained that it was reworking its sales team for rare disease medicines, including chronic myeloid leukemia treatment Tasigna and platelet-stimulating agent Promacta, both of which are losing patent protection this year. Two months later in May, Novartis said it would chop another 76 positions, with the company citing a downsizing of its biomedical research arm. A few weeks after that, the company telegraphed an additional 60 job cuts, saying that it had “taken steps to evolve our Oncology, Rheumatology, Dermatology and Neuroscience field sales teams in the U.S." Novartis is feeling the pinch of the loss of exclusivity (LOE) of megablockbuster heart failure medicine Entresto, which began in July of last year. Revenue from the heart failure medicine plummeted from $2.3 billion in the first quarter of 2025 to $1.3 billion in this year’s first quarter. With the dropoff, Novartis saw its overall sales decline in the first quarter by 1%, this coming after the company reported revenue increases of 12% in 2024 and 8% in 2025. In March of 2025, Novartis also slashed 427 jobs, citing the upcoming LOE of Entresto. Novartis has been working to adjust and right-size its operations since 2022, when it merged its oncology and pharmaceuticals units into one innovative medicines business, now managed by geographic regions.

01 Jun 2026

·www.fiercebiotech.com

Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study

Oscotec’s phase 2 trial missed its primary goal of demonstrating that cevidoplenib could double a patient’s platelet count after 12 weeks of treatment.\n Days after its lead clinical-stage drug suffered a setback, Agios Pharmaceuticals has rebounded by buying a blood disorder drug that flunked a phase 2 study.The prize is an oral spleen tyrosine kinase (SYK) inhibitor called cevidoplenib, which has been developed by Korea’s Oscotec. The biopharma has already taken cevidoplenib into a phase 2 study of 60 patients with a rare autoimmune blood disorder called immune thrombocytopenia (ITP).ITP affects around 200,000 people worldwide, including 90,000 in the U.S. alone, according to Agios. The condition is characterized by an immune system that destroys platelets, leading to an increased risk of bleeding.Oscotec’s phase 2 trial missed its primary goal of demonstrating that cevidoplenib could double a patient’s platelet count after 12 weeks of treatment. But Agios was undeterred, pointing to “durable and clinically meaningful platelet responses observed in the cevidoplenib arm compared with placebo across multiple secondary endpoints that align with primary endpoints used in ITP registrational trials.”Agios’ plan is to take the therapy into phase 3 trials in the first half of 2028, once it has completed additional chemistry, manufacturing, and controls (CMC) development work.Many patients with ITP receive steroids or thrombopoietin receptor agonists, such as Amgen’s Nplate or Novartis’ Promacta. Roche’s Rituxan is also used off-label to treat the condition in the U.S., though the antibody comes with some trade-offs when deployed against ITP. Meanwhile, Sanofi’s Wayrilz became the first BTK inhibitor to score an FDA approval for the clotting disease last year.Agios claimed that while current standard-of-care therapies are focused on increasing platelet counts and reducing bleeding risk, they are “often associated with limitations, including delayed onset of response, lack of durable efficacy, and class-specific adverse events, such as decreased blood counts and an increased risk of infections.”In return for the exclusive global rights to cevidoplenib, the Cambridge, Massachusetts-based biopharma is paying $25 million upfront and is liable for up to a further $140 million in development and regulatory milestones across up to three indications in the U.S. and Europe. If the drug secures an approval, Oscotec could also be in line for commercial milestone payments as well as royalties ranging from high single digit to mid-teens.Once the drug has cleared a phase 3 trial, Seongnam-based Oscotec has the option to secure the right to commercialize cevidoplenib on its home turf of South Korea.Cevidoplenib’s focus on ITP falls within Agios’ comfort zone of blood disorders. The biopharma’s sole commercial product is Pyrukynd, a PK activator that won approval in 2022 as the first therapy indicated for hemolytic anemia in adults with PK deficiency and has since expanded to treat anemia in adults with alpha- or beta-thalassemia under the brand name Aqvesme. Last week, Agio’s next-gen PK drug tebapivat failed a phase 2 study in lower-risk myelodysplastic syndromes, but the company is still persevering with the therapy in sickle cell disease.

Phase 2Drug ApprovalPhase 3Immunotherapy

21 May 2026

·www.biospace.com

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Pluvicto ® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali ® NATALEE oral presentation to report prognostic and predictive impact of gene expression from largest biomarker CDK4/6i trial dataset Scemblix ® ASC4FIRST oral presentation to feature longer-term 144-week efficacy, safety and tolerability data in first-line Ph+ CML-CP New Novartis pipeline data, including Phase 3 ianalumab in ITP as well as Phase 1 actinium-based radioligand therapy, also to be presented Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress. “We are excited about sharing our latest advancements in radioligand therapy with new Pluvicto data and early insights from our actinium-based RLT,” said Mark Rutstein, MD, Global Head, Oncology Development, Novartis. “With a legacy of bold science, our Kisqali and Scemblix data offer continued evidence of how we meaningfully move cancer treatment forward for patients.” Key ASCO data highlights include: Abstract Title Abstract Number/ Presentation Details Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Subgroup Analyses by Disease Volume and De Novo/Recurrent mHSPC in the PSMAddition Study of [ 177 Lu]Lu-PSMA-617 225 Ac-PSMA-617 AcTION: Phase 1 Study of [ 225 Ac]Ac-PSMA-617 (225Ac-PSMA-617) in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With or Without Prior [ 177 Lu]Lu-PSMA (177Lu-PSMA) Radioligand Therapy (RLT) Abstract # 5020 Rapid Oral May 31, 4:30pm – 6:00pm CDT Abstract # 5010 Oral June 1, 3:00pm – 4:30pm CDT Scemblix (asciminib) ASC4FIRST wk 144 Analysis: Efficacy and Safety and Tolerability With Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS TKIs) in Newly Diagnosed (ND) chronic myeloid leukemia in Chronic Phase (CML-CP) Abstract #6583 Poster June 1, 9:00am – 12:00pm CDT Kisqali (ribociclib) Prognostic and Predictive Impact of Baseline Gene Expression (Exp) in the NATALEE Trial of Adjuvant (Adj) Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) in HR+/HER2− Early Breast Cancer (EBC) Abstract #501 Oral May 30, 1:15pm – 4:15pm CDT Real-World (RW) Post-Progression Outcomes Following First-Line (1L) Ribociclib (RIB) + Aromatase Inhibitor (AI) Versus AI Alone in African American and Low Socio-Economic Status (SES) Patients (Pts) With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) in the US Abstract #1073 Poster June 1, 1:30pm – 4:30pm CDT Real-World (RW) Post-Progression Outcomes After First-Line (1L) Treatment With Ribociclib + an Aromatase Inhibitor (AI) vs AI Alone in US Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) Abstract # e13044 Online publication Key EHA data highlights include:  Abstract Title Abstract Number/ Presentation Details Scemblix (asciminib) ASC4FIRST wk 144 Analysis: Continued Superior Efficacy and Favorable Safety of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Abstract # S160 Oral June 11, 4:45pm – 6:00pm CEST Ianalumab (VAY736) Effect of Ianalumab Plus Eltrombopag on Patient-Reported Outcomes in Primary Immune Thrombocytopenia: Results From the VAYHIT2 Phase 3 Trial Abstract # PF1340 Poster June 12, 6:45pm – 7:45pm CEST Pelabresib (DAK539) Pelabresib Monotherapy in Myelofibrosis After Janus Kinase Inhibitor Failure: Results From Arm 1 of the Open-Label, Phase 2 MANIFEST Study Abstract # PS1987 Poster June 13, 6:45pm – 7:45pm CEST Rapcabtagene autoleucel (YTB323) Safety, Cellular Kinetics and Early Efficacy of Rapcabtagene Autoleucel (YTB323), a Rapidly Manufactured Autologous CD19 CAR-T Therapy, in Severe, Refractory Autoimmune Diseases Abstract # PF1241 Poster June 12, 6:45pm – 7:45pm CEST Fabhalta ® (iptacopan) Iptacopan demonstrates sustained efficacy and safety in paroxysmal nocturnal hemoglobinuria: up to 4 years of follow-up in patients from APPLY, APPOINT and roll-over extension program Abstract #PS1788 Poster June 13, 6:45pm – 7:45pm CEST Long-term hematologic control and safety in patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: 6-year follow-up from phase 2 studies and roll-over extension program Abstract # PS1797 Poster June 13, 6:45pm – 7:45pm CEST Novartis in oncology The Novartis oncology strategy focuses on people living with cancer and those who care for them, from loved ones to clinical care teams, including their providers. For the past 30+ years, the aim has been to extend and improve lives by discovering differentiated, innovative and practice-changing medicines for patients. As Novartis reimagines medicine, it collaborates with a wide range of patient advocacy groups and supports education, early cancer screening and diagnosis. With a broad research and development portfolio across solid tumors, hematology and radioligand therapy (RLT), Novartis is committed to using technology, leading science and patient-centered research to deliver pioneering cancer care for all those in need. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . # # # Novartis Media Relations E-mail: media.relations@novartis.com Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

ASCOPhase 2Clinical ResultImmunotherapyPhase 3

100 Deals associated with Eltrombopag Diolamine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Eltrombopag Diolamine	B02BX05	DB06210

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heparin-induced thrombocytopenia	Australia	Novartis Pharmaceuticals Australia Pty Ltd.	12 Sep 2024
Anemia, Aplastic	European Union	Novartis Europharm Ltd.	11 Mar 2010
Anemia, Aplastic	Iceland	Novartis Europharm Ltd.	11 Mar 2010
Anemia, Aplastic	Liechtenstein	Novartis Europharm Ltd.	11 Mar 2010
Anemia, Aplastic	Norway	Novartis Europharm Ltd.	11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic	European Union	Novartis Europharm Ltd.	11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic	Iceland	Novartis Europharm Ltd.	11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic	Liechtenstein	Novartis Europharm Ltd.	11 Mar 2010
Purpura, Thrombocytopenic, Idiopathic	Norway	Novartis Europharm Ltd.	11 Mar 2010
Thrombocytopenia	United States	Novartis Pharmaceuticals Corp.	20 Nov 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myelodysplastic Syndromes	Phase 3	Austria	GlaxoSmithKline Research & Development Ltd.	25 Jul 2014
Neoplasms	Phase 3	Austria	GlaxoSmithKline Research & Development Ltd.	25 Jul 2014
Solid tumor	Phase 3	Taiwan Province	Novartis AG	01 Mar 2014
Contusions	Phase 3	United States	GSK Plc	01 Mar 2012
Contusions	Phase 3	Argentina	GSK Plc	01 Mar 2012
Contusions	Phase 3	Czechia	GSK Plc	01 Mar 2012
Contusions	Phase 3	Germany	GSK Plc	01 Mar 2012
Contusions	Phase 3	Hong Kong	GSK Plc	01 Mar 2012
Contusions	Phase 3	Israel	GSK Plc	01 Mar 2012
Contusions	Phase 3	Italy	GSK Plc	01 Mar 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2026	Not Applicable	Anemia, Aplastic First line	40	Eltrombopag+Cyclosporine	rkvdbqgzgz(hsusnowuqn) = vrdvgfwrii xljqhayzel (tfipcattqu ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Anemia, Aplastic	40	ATG eltrombopagCSA (pre-eltrombopag era (before 2018))	bswvkdqotj(kwvzxpvwca) = kdmquwtskr siqrmzkgyp (rkpecmurxa )	Positive	12 May 2026
				ATG ±eltrombopagCSA (post-eltrombopag era)	bswvkdqotj(kwvzxpvwca) = qwtawhqhvw siqrmzkgyp (rkpecmurxa )
EHA2026	Not Applicable	Acute Myeloid Leukemia	51	Eltrombopag plus VA	pmpixddhrv(umtvkdegpg) = vfrqpesbts naururjgau (aajtamnkhq, 4.4 - 34.9) View more	Positive	12 May 2026
				VA	pmpixddhrv(umtvkdegpg) = ngkfkufbaw naururjgau (aajtamnkhq, 18.0 - 57.5) View more
NCT02773225 (EMAA, EHA2026)	Phase 3	Anemia, Aplastic First line	85	Eltrombopag 150 mg/day + Cyclosporine	kuibjgvkev(blypcygmoe) = prgnflqyeo lhifdaxjai (zucnfcwqmd, 36.14 - NA) View more	Positive	12 May 2026
				Placebo + Cyclosporine	kuibjgvkev(blypcygmoe) = kqzbslmghy lhifdaxjai (zucnfcwqmd, 24.00 - 56.14) View more
NCT03413306 (EHA2026)	Phase 3	Refractory Severe Aplastic Anemia	200	Eltrombopag + IST	ecoatohdyr(ekpajdmkoi): P-Value = 0.034 View more	Positive	12 May 2026
				IST
EHA2026	Not Applicable	Multiple Myeloma \| Hematologic Neoplasms \| Lymphoma	55	Hetrombopag	gqluwsgqkl(iiaqolrzsh) = All adverse events were grade 1-2 and resolved with symptomatic management. Common events included fever, headache, dizziness, diarrhea, fatigue, rash, elevated transaminases, and renal dysfunction. No grade ≥3 adverse events were observed. gjpzpnsiry (xtuyqotlhh ) View more	Positive	12 May 2026
				Eltrombopag
EHA2026	Not Applicable	Purpura, Thrombocytopenic, Idiopathic	120	Eltrombopag	gkmgbfjjlx(qdnuwziidl) = fxxhqdvjih njnckfvpqk (jewynbevjd ) View more	Positive	12 May 2026
				Romiplostim	gkmgbfjjlx(qdnuwziidl) = zuhkkvsaal njnckfvpqk (jewynbevjd ) View more
NCT05653219 (VAYHIT2, N Engl J Med \| Company_Website) Manual	Phase 3	Purpura, Thrombocytopenic, Idiopathic Second line	152	Ianalumab 9 mg + Eltrombopag	iqsngggkxh(aftcpwoaeo) = ncaowpvayf ywgcbowdhl (ldlhutetkw, 39 - 67) View more	Positive	09 Dec 2025
				Ianalumab 3 mg + Eltrombopag	iqsngggkxh(aftcpwoaeo) = wubigvgyky ywgcbowdhl (ldlhutetkw, 36 - 64) View more
NCT05653219 (VAYHIT2, Pubmed \| N Engl J Med)	Phase 3	Purpura, Thrombocytopenic, Idiopathic Second line	152	Ianalumab 9 mg	pbimrdztrc(ahpwkkamhy) = emlvaewogm olcnfkwlup (tcmfcfolgt ) View more	Positive	09 Dec 2025
				Ianalumab 3 mg	wcbhiobjpq(bvhqutfkqx) = rixvirkwqc gelebdmsfc (yihzoxqoak, 36 - 64) View more
ASH2025	Not Applicable	Purpura, Thrombocytopenic, Idiopathic First line	103	Dexamethasone and Eltrombopag (DE)	zbpmtgafaq(ojqisjqhgn) = hyrujtlmab pdaylkulen (omhgeuzwds ) View more	Positive	06 Dec 2025
				Dexamethasone, Eltrombopag and Azathioprine (DEA)	zbpmtgafaq(ojqisjqhgn) = zajgcuaqro pdaylkulen (omhgeuzwds ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Eltrombopag Diolamine

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation